Abstract CT316: A phase I trial of oral TRC102 (methoxyamine HCl) in combination with temozolomide (TMZ) in patients with relapsed solid tumors
Woondong Jeong(National Cancer Institute), Shivaani Kummar(Oregon Health & Science University), Elad Sharon(National Cancer Institute), Jerry M. Collins(National Institutes of Health), James H. Doroshow(National Cancer Institute), Alice P. Chen(National Institutes of Health), Richard Piekarz(Yeshiva University), Barbara A. Conley(National Cancer Institute), Priya Balasubramanian(Arc of the United States), Larry Anderson(The University of Texas Southwestern Medical Center), Lamin Juwara(Frederick National Laboratory for Cancer Research), T. Khanh(Brigham and Women's Hospital), Yvonne Horneffer(National Cancer Institute), Robert J. Kinders(National Cancer Institute), Howard Streicher(National Cancer Institute), Lihua Wang(Jiangxi University of Traditional Chinese Medicine), Jennifer Zlott(National Cancer Institute)
Cited by 1
Related Papers
Ipilimumab for Patients with Relapse after Allogeneic Transplantation
|New England Journal of Medicine|2016|601
Institutional implementation of clinical tumor profiling on an unselected cancer population
|JCI Insight|2016|447
Current Landscape of Immunotherapy in Breast Cancer
|JAMA Oncology|2019|409
Lnc2Cancer: a manually curated database of experimentally supported lncRNAs associated with various human cancers
|Nucleic Acids Research|2015|386